Biotech entity
WVE-006 is most often covered alongside GSK, which appears in 2 of these 2 stories. Across a 160-day span, the pace is roughly 0.1 stories per week. The 5 average consequence score is below the beat benchmark of 6.2 in the same window.
Last mentioned: Aug 4, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
WVE-006 is most often covered alongside GSK, which appears in 2 of these 2 stories. Across a 160-day span, the pace is roughly 0.1 stories per week. The 5 average consequence score is below the beat benchmark of 6.2 in the same window. They are less corroborated than the beat average, carrying 2 original sources each against 3.7 for the same window. clinical-trial accounts for 1 of the 2 tracked stories, while 1 other category carries the remainder. We currently track 2 Biotech stories that mention WVE-006, published between February 26, 2026 and August 4, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 585 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering WVE-006. Shared-story counts are live from our verified record — not editorial picks.
Wave Life Sciences presented Phase I data for WVE-007, an siRNA targeting Activin E, demonstrating up to 88% serum reduction sustained for over 7.5 months. The INLIGHT Phase IIa trial is now enrolling 160 patients across four cohorts, with a focus on BMI 35–50 and type 2 diabetes status, aiming to validate the RNA editing platform's potential for durable obesity treatment.
Wave Life Sciences and Collegium Pharmaceutical reported full-year 2025 results, highlighting a transformative period for RNA editing and commercial pain management. Wave's clinical progress in AATD and DMD remains a primary valuation driver, while Collegium continues to optimize its specialized portfolio through strategic acquisitions.
WVE-006 is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
